BRASH Syndrome with Hyperkalemia: An Under-Recognized Clinical Condition

Area of Science:

• Cardiology
• Nephrology
• Clinical Pharmacology

Background:

• Atrioventricular nodal blockers (AVNBs) are frequently used for rate control in various cardiac conditions.
• Patients with chronic kidney disease or low glomerular filtration rate (GFR) often require medication adjustments due to decreased drug clearance.
• The potential for drug accumulation and toxicity in renally impaired patients is a significant clinical concern.

Observation:

• BRASH syndrome is a newly recognized clinical entity characterized by five key features: Bradycardia, Renal failure, Atrioventricular nodal blocker (AVNB) use, Shock, and Hyperkalemia.
• Patients presenting with BRASH syndrome exhibit a complex interplay between medication effects and deteriorating renal function.
• The syndrome appears to be driven by a vicious cycle where initial bradycardia and renal impairment are exacerbated by AVNB accumulation.

Findings:

• Reduced GFR leads to decreased clearance of AVNBs, increasing serum drug concentrations.
• Elevated AVNB levels potentiate bradycardia and contribute to hypoperfusion and shock.
• Hyperkalemia, a consequence of renal failure, further exacerbates bradycardia and impairs cardiac function.
• The resulting hypoperfusion worsens renal function, creating a self-perpetuating cycle.

Implications:

• Recognition of BRASH syndrome is crucial for timely diagnosis and intervention in at-risk patients.
• Management requires addressing both the AVNB toxicity and the underlying renal failure.
• This syndrome highlights the importance of considering renal function when prescribing AVNBs, especially in vulnerable populations.
• Further research is needed to elucidate the precise mechanisms and optimize treatment strategies for BRASH syndrome.